B
Brittany L. Hartwell
Researcher at Massachusetts Institute of Technology
Publications - 15
Citations - 352
Brittany L. Hartwell is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Experimental autoimmune encephalomyelitis & Antigen. The author has an hindex of 9, co-authored 14 publications receiving 241 citations. Previous affiliations of Brittany L. Hartwell include University of Kansas.
Papers
More filters
Journal ArticleDOI
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice.
Neil C. Dalvie,Sergio A. Rodriguez-Aponte,Brittany L. Hartwell,Lisa H. Tostanoski,Andrew M. Biedermann,Laura E. Crowell,Kawaljit Kaur,Ozan S. Kumru,Lauren Carter,Jingyou Yu,Aiquan Chang,Katherine McMahan,Thomas Courant,Celia Lebas,Ashley A. Lemnios,Kristen A Rodrigues,Murillo Silva,Ryan S Johnston,Christopher A Naranjo,Mary Kate Tracey,Joseph R. Brady,Charles A. Whittaker,Dongsoo Yun,Natalie Brunette,Jing Yang Wang,Carl Walkey,Brooke Fiala,Swagata Kar,Maciel Porto,Megan Lok,Hanne Leth Andersen,Mark G. Lewis,Kerry R. Love,Danielle L Camp,Judith M. Silverman,Harry Kleanthous,Sangeeta B. Joshi,David B. Volkin,Patrice M. Dubois,Nicolas Collin,Neil P. King,Dan H. Barouch,Dan H. Barouch,Darrell J. Irvine,Darrell J. Irvine,J. Christopher Love +45 more
TL;DR: In this article, an engineered sequence variant of RBD that exhibits high-yield manufacturability, high-affinity binding to ACE2, and enhanced immunogenicity after a single dose in mice compared to the Wuhan-Hu-1 variant used in current vaccines.
Journal ArticleDOI
Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitis
Joshua Sestak,Bradley P. Sullivan,Sharadvi Thati,Laura Northrup,Brittany L. Hartwell,Lorena R. Antunez,M. Laird Forrest,Charlotte M. Vines,Teruna J. Siahaan,Cory Berkland +9 more
TL;DR: Carriers that codeliver antigen and a secondary “context” signal (e.g., LABL) in vivo may be an important design criteria to consider when designing antigen-SIT for autoimmune therapy.
Journal ArticleDOI
Multivalent Nanomaterials: Learning from Vaccines and Progressing to Antigen‐Specific Immunotherapies
Brittany L. Hartwell,Lorena R. Antunez,Bradley P. Sullivan,Sharadvi Thati,Joshua Sestak,Cory Berkland +5 more
TL;DR: This review highlights multivalent ligand display on linear polymers, the complex interplay of physical parameters in multivalent design, and the ability to direct the immune response by molecular and transport mechanisms.
Journal ArticleDOI
Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis
Laura Northrup,Joshua Sestak,Bradley P. Sullivan,Sharadvi Thati,Brittany L. Hartwell,Teruna J. Siahaan,Charlotte M. Vines,Cory Berkland +7 more
TL;DR: This antigen-specific immunotherapy using SAgAs can successfully suppress EAE through co-delivery of autoantigen and peptides targeting with the B7 signaling pathway.
Journal ArticleDOI
Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis
Brittany L. Hartwell,Chad J. Pickens,Martin A. Leon,Laura Northrup,Matthew A. Christopher,J. Daniel Griffin,Francisco J. Martinez-Becerra,Cory Berkland +7 more
TL;DR: Key therapeutic molecular properties of SAgAs were identified and linked to the immunological mechanism through comprehensive cellular and in vivo analyses and this work guides the design of antigen-specific immunotherapies capable of inducing anergy.